Europe Biosimulation Market (2026-2031)
The Europe Biosimulation Market was valued at $664.4 Million in 2026 and projected to reach to $1463 Million by 2031, representing a compound annual growth rate of 17.1%. Europe's biosimulation market is positioned for substantial growth, driven by regulatory modernization, increased R&D investments, and a strong commitment to reducing animal testing.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe Biosimulation Market Trends and Insights
- This 17.1% compound annual growth rate reflects Europe's strong commitment to advanced computational drug development and regulatory modernization.
- Europe is leveraging biosimulation technologies to accelerate pharmaceutical R&D, reduce animal testing, and optimize clinical trial design across major markets including Germany, France, and the United Kingdom. The European biosimulation landscape is driven by stringent regulatory frameworks, substantial investment in life sciences infrastructure, and growing adoption among contract research organizations (CROs) and biopharmaceutical companies.
- Europe's emphasis on precision medicine and personalized therapeutics is propelling demand for in silico modeling and simulation platforms.
- By 2031, Europe is expected to solidify its position as a global leader in biosimulation adoption, supported by collaborative research initiatives and digital health innovation ecosystems..
Key Market Statistics
- CAGR (2026-2031) 17.1% CAGR
- Market Size, 2026 ~USD 664.4 Million
- Forecast, 2031 ~USD 1463 Million
- Geography Europe
Europe Biosimulation Market Overview
Strong CAGR Trajectory :
Europe's biosimulation market is growing at 17.1% CAGR from 2026 to 2031, outpacing the global average of 16.7%, demonstrating the region's accelerated adoption of computational drug development technologies.
Regulatory Leadership :
European regulatory bodies, particularly the EMA, are actively promoting biosimulation integration into drug approval processes, reducing reliance on animal testing and expediting time-to-market for pharmaceutical innovations.
Market Expansion Potential :
The European market is projected to more than double from $664.4 million in 2026 to $1,463.0 million by 2031, reflecting sustained investment in computational biology and precision medicine initiatives across the continent.
R&D Modernization Focus :
European pharmaceutical companies are increasingly leveraging biosimulation to optimize clinical trial design, reduce development costs, and accelerate drug candidate progression through preclinical and clinical phases.
Europe Biosimulation Market Dynamics
- The region's advanced healthcare infrastructure and stringent regulatory frameworks create an ideal environment for biosimulation adoption.
- Major pharmaceutical hubs in Germany, France, and the UK are spearheading innovation in computational drug development. The forecast period through 2031 will see biosimulation becoming integral to European drug development pipelines.
- Continued EMA support, rising collaboration between academic institutions and industry, and growing awareness of biosimulation's cost-effectiveness will propel market expansion.
- Europe's emphasis on personalized medicine and precision therapeutics further accelerates demand for sophisticated simulation technologies..
Related Ecosystem
Healthcare It
Key Takeaways
- Europe's biosimulation market is valued at $664.4 million in 2026 and projected to grow to $1,463.0 million by 2031, representing a 17.1% CAGR.
- Europe's regulatory environment and emphasis on reducing animal testing are major drivers accelerating biosimulation adoption across the region.
- Germany, France, and the United Kingdom are leading European markets, with strong CRO and biopharmaceutical sector engagement in biosimulation technologies.
- Europe's focus on precision medicine and personalized therapeutics is expected to sustain double-digit growth through 2031.
Biosimulation Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | DATA ANALYSIS & INTERPRETATION (Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 16.7% from 2026 to 2031 |
| Largest Segment | SOFTWARE (Offering) |
| Market Size Base Year (Billions) | ~USD 4.27 (2026) |
| Revenue Forecast (Billions) | ~USD 9.24 (2031) |
| Segments Covered | Offering, Type, Phase Of Development |
Europe Biosimulation Market Report Segmentation
3 segment dimensions are covered across the global market.
By Offering
- Services
- Software
By Type
- Consulting & Advisory
- Data Analysis & Interpretation
- Implementation, Training, And Support
By Phase Of Development
- Commercial & Market Access
- Drug Discovery
- Early Clinical Development
- Late Clinical Development
- Preclinical Development
- Regulatory
Target Audience
- Pharmaceutical Companies : European pharma firms need market intelligence to optimize R&D investments, accelerate drug development timelines, and align with EMA regulatory expectations for biosimulation integration.
- Contract Research Organizations (CROs) : European CROs require detailed market data to expand biosimulation service offerings, identify client demand patterns, and position themselves competitively within the growing regional market.
- Software & Technology Vendors : Biosimulation software providers need Europe-specific market insights to tailor solutions for regional regulatory requirements, identify high-growth country markets, and develop localized go-to-market strategies.
- Regulatory & Compliance Consultants : Consultants advising European biotech and pharma clients need comprehensive market data to guide regulatory strategy, demonstrate biosimulation ROI, and support EMA submission preparations.
- Investment & Private Equity Firms : Investors targeting European life sciences need market forecasts, growth drivers, and competitive analysis to identify acquisition targets and evaluate portfolio company potential in biosimulation.
Key Companies in the Europe Biosimulation Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SANOFI | France | Public Company | Pediatric and combination vaccines (polio, pertussis, Hib, hexavalent),Other vaccines (RSV, hepatitis A, typhoid, yellow fever, rabies),Immunology and inflammation therapies, |
| CERTARA | United States | Public Company | Biosimulation platforms (Simcyp, Phoenix, NLME, Pirana),Regulatory data and submission software (Pinnacle 21, GlobalSubmit, CoAuthor, Metadata Repository),Discovery and informatics solutions (Chemaxon suite, D360, design tools), |
| DASSAULT SYSTÈMES | France | Public Company | 3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA), |
| SCHRöDINGER, INC. | United States | Public Company | Software,Drug Discovery – Collaborations (e.g., Novartis),Drug Discovery – Internal Pipeline, |
| SIMULATIONS PLUS | United States | Public Company | PBPK/PKPD and biopharmaceutics software (GastroPlus, DDDPlus, MembranePlus),QSP and disease-systems platforms (DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, Thales),ADMET Predictor, MedChem Designer and discovery-oriented AI/ML tools, |
| PHYSIOMICS PLC | United Kingdom | Public Company | Oncology modeling & simulation (Virtual Tumour–centric consulting),Broader quantitative pharmacology & computational biology services,Personalized medicine technology and related analytics, |
| INSTEM PLC | United Kingdom | Private Company | Research study management software (discovery, preclinical, early clinical),Regulatory submission and SEND-compliant dataset solutions,In silico and data insights / predictive analytics, |
SANOFI
Sanofi is a French multinational pharmaceutical company founded in 1994 with 74,846 employees. As a public company, it operates globally in the development, manufacturing, and distribution of medicines and vaccines.
CERTARA
Certara is a United States-based public company founded in 2008 with 1,546 employees. It provides software and services for drug development, including modeling, simulation, and regulatory consulting.
DASSAULT SYSTÈMES
Dassault Systèmes is a French software company founded in 1981 with 25,724 employees. As a public company, it develops 3D design, simulation, and digital lifecycle management solutions for various industries.
SCHRöDINGER, INC.
Schrödinger, Inc. is a United States-based public company founded in 1990 with 850 employees. It provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.
SIMULATIONS PLUS
Simulations Plus is a United States-based public company founded in 1996 with 213 employees. It develops software for drug development, including pharmacokinetic and pharmacodynamic modeling and simulation.
PHYSIOMICS PLC
Physiomics PLC is a United Kingdom-based public company founded in 2001 with 10 employees. It specializes in computational biology and systems pharmacology for drug development.
INSTEM PLC
Instem PLC is a United Kingdom-based private company founded in 1969 with 510 employees. It provides software and services for data management and analysis in preclinical and clinical research.
Countries within Europe - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Germany | USD 686.8 Million |
| France | USD 543.6 Million |
| UK | USD 485.8 Million |
| Italy | USD 166.1 Million |
| Spain | USD 133.7 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Sizing : Obtain precise market valuations for Europe's biosimulation sector with country-level breakdowns for Germany, France, UK, Italy, and Spain, enabling targeted investment and expansion strategies.
- Competitive Landscape Intelligence : Understand Europe-specific competitive dynamics, key players, and market consolidation trends to identify partnership opportunities and competitive positioning within the region.
- Regulatory Insights : Access detailed analysis of EMA guidelines, European regulatory pathways, and how biosimulation is reshaping drug approval processes across member states.
- Growth Forecasting : Leverage accurate 2026-2031 projections and 17.1% CAGR data to inform strategic planning, resource allocation, and market entry timing for European operations.
- End-User Demand Analysis : Identify specific needs of European pharmaceutical companies, CROs, and biotech firms driving biosimulation adoption, enabling tailored product and service development.
Frequently asked questions
What is the current size of Europe's biosimulation market?
Europe's biosimulation market was valued at $664.4 million in 2026 and is projected to reach $1,463.0 million by 2031.
What is the growth rate of biosimulation in Europe?
Europe's biosimulation market is growing at a compound annual growth rate (CAGR) of 17.1% from 2026 to 2031.
Which countries are driving Europe's biosimulation market?
Germany, France, and the United Kingdom are the leading markets in Europe, driven by strong pharmaceutical R&D infrastructure and regulatory support for computational modeling.
What factors are accelerating biosimulation adoption in Europe?
Europe's stringent regulatory frameworks, emphasis on reducing animal testing, investment in life sciences infrastructure, and growing adoption by CROs and biopharmaceutical companies are key growth drivers.
How is Europe using biosimulation in drug development?
Europe is leveraging biosimulation to accelerate pharmaceutical R&D, optimize clinical trial design, reduce animal testing, and support precision medicine and personalized therapeutic development.
RESEARCH METHODOLOGY
This research study involved the extensive use of both primary and secondary sources. It involved the analysis of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.
Secondary Research
This research study extensively utilized secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The secondary research aimed to gather and analyze information for a comprehensive and commercially focused study of the biosimulation market, encompassing technical aspects and market dynamics. It also facilitated the identification of key players, market classification, industry trends, geographical markets, and significant market-related developments. Additionally, a database of prominent industry leaders was compiled through secondary research.
Primary Research
In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the biosimulation market. Primary sources from the demand side included personnel from pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and regulatory bodies.
A breakdown of the primary respondents is provided below:
Note: Tiers are defined based on a company’s total revenue, as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million. Other designations include sales managers, marketing managers, and product managers.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the biosimulation market was determined after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.
Biosimulation Market : Top-Down and Bottom-Up Approach
Data Triangulation
The size of the biosimulation market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as follows: -
- Revenues for individual companies were gathered from public sources and databases.
- Shares of leading players in the biosimulation market were gathered from secondary sources to the extent available. In certain cases, shares of biosimulation businesses were ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, and geographic reach & strength.
- Individual shares or revenue estimates were validated through interviews with experts.
- The total revenue in the biosimulation market was determined by extrapolating the market share data of major companies.
Market Definition
Biosimulation is a technology that employs computer-aided simulations to replicate and predict the dynamics of biological processes and systems. It uses modern computational power to analyze and model biological behavior through mathematical expressions. Biosimulation, often referred to as Computer-aided Drug Design (CADD), plays a critical role in various stages of drug discovery and development. Leveraging AI and machine learning, biosimulation enhances the evaluation of drug safety, efficacy, and interactions, ultimately streamlining clinical trial design and accelerating time-to-market for new therapeutics.
Key Stakeholders
- Clinical/Physician centers
- Biosimulation vendors
- Clinical research organizations
- Pharmaceutical/Biopharmaceutical companies
- Research & development (R&D) companies
- Business research and consulting service providers
- Medical research laboratories
- Academic medical centers/Universities/Hospitals
- Regulatory agencies
- Clinical researchers
- Accountable care organizations
- Investors and venture capitalists
Report Objectives
- To define, describe, and forecast the biosimulation market based on offering, phase of development, modality, application, therapeutic area, deployment mode, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biosimulation market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, and collaborations in the overall biosimulation market
- To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
- Company information
- Detailed analysis and profiling of additional market players (up to 5)
Regional Analysis
- Further breakdown of the Rest of Asia Pacific biosimulation market into Taiwan, New Zealand, Thailand, Singapore, Malaysia, and other countries
- Further breakdown of the Rest of Europe biosimulation market into Russia, Austria, Finland, Sweden, Turkey, Norway, Poland, Portugal, Romania, Denmark, and other countries
Get the Full Biosimulation Market Report
Full forecast, segment splits, and company analysis for all Biosimulation Market.
- US Biosimulation Market
- Canada Biosimulation Market
- Germany Biosimulation Market
- France Biosimulation Market
- UK Biosimulation Market
- Italy Biosimulation Market
- Spain Biosimulation Market
- China Biosimulation Market
- Japan Biosimulation Market
- India Biosimulation Market
- Australia Biosimulation Market
- South Korea Biosimulation Market
- Brazil Biosimulation Market
- Mexico Biosimulation Market
- Saudi Arabia Biosimulation Market
- UAE Biosimulation Market
- South Africa Biosimulation Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report